01
07
2022
In June 2021, DAC Biotech successfully declared the first ADC drug targeting Muc1 in China. (In the development of this drug, Medicilon provided pre-clinical research services including efficacy, pharmacokinetics, and safety evaluation).
01
05
2022
As a collaborative partner of Regor, Shanghai Medicilon Inc. (Medicilon) provided RGT-419B with a toxicological DRF test that complies with GLP specifications to accelerate the project's R&D process.
11
26
2021
In just 10 days, Medicilon helped 3 bispecific antibody therapeutic drugs to be approved! This is another achievement of the high-quality construction of Medicilon's one-stop preclinical medicine R&D service platform. Behind these remarkable achievements, it is inseparable from the efforts and dedication of every researcher in Medicilon.
10
18
2021
On October 12, the sub-forum of International Biopharm Industry Week Shanghai 2012 - Zhangjiang Life Science International Innovation Summit hosted by Shanghai Medicilon Inc. (Medicilon), Internationalization Trend of Chinese Pharmaceutical Companies and AI R&D Innovation Forum and Zhangjiang AI New Drug R&D Alliance Establishment Conference was successfully held in Shanghai.
09
22
2021
In the field of IL-23 monoclonal antibody drug research and development, Medicilon's Pharmacodynamics Department has been deeply involved for many years, has an excellent evaluation ability of animal efficacy evaluation models, and strictly complies with the GLP specifications of NMPA, OECD and FDA.
